Kyntra Bio Presents Roxadustat-Focused Strategy After Ending FG-3246 Program

By Public Technologies
  • Kyntra Bio terminated FG-3246 and FG-3180 in fourth-quarter 2026 following insufficient efficacy in a planned Phase 2 interim analysis.
  • The termination returns FG-3246 rights to Fortis Therapeutics, reducing operating expenses by over $20 million in 2027 and 2028.
  • Resources shift to roxadustat for anemia in lower-risk MDS; Phase 3 initiation is expected in first-quarter 2027, contingent on partnership or external financing.
  • Royalty restructuring reduced maximum aggregate payment obligations by $60 million, leaving $15 million in future royalty-backed payments.
  • Cash runway is expected to extend into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.